ENB 824
Alternative Names: ENB-824Latest Information Update: 05 Dec 2023
At a glance
- Originator Engine Biosciences
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 05 Dec 2023 ENB 824 is available for licensing as of 05 Dec 2023. https://www.enginebio.com/partnering/
- 27 Nov 2023 Early research in Solid tumours in Singapore (Engine Biosciences pipeline, November 2023)